Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial. [electronic resource]
Producer: 20120319Description: 3093-100 p. digitalISSN:- 1432-0428
- Adult
- Aged
- Animals
- Body Weight -- drug effects
- Diabetes Mellitus, Type 2 -- blood
- Disease Models, Animal
- Drug Therapy, Combination
- Edema -- chemically induced
- Exenatide
- Fatty Liver -- drug therapy
- Female
- Fibroblast Growth Factors -- antagonists & inhibitors
- Humans
- Hypoglycemic Agents -- therapeutic use
- Liver -- drug effects
- Lower Extremity -- physiopathology
- Male
- Metformin -- therapeutic use
- Mice
- Middle Aged
- Nausea -- chemically induced
- Non-alcoholic Fatty Liver Disease
- Obesity -- metabolism
- Peptides -- adverse effects
- Pioglitazone
- Thiazolidinediones -- therapeutic use
- Venoms -- adverse effects
No physical items for this record
Publication Type: Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.